The staging of sepsis: Understanding heterogeneity in treatment efficacy

Critical Care

Volumn 9, Issue 6, 2005, Pages 626-628

  Marshall, John C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DROTRECOGIN; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; VASOACTIVE AGENT; PROTEIN C;

ADJUVANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MORTALITY; NOTE; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; APACHE; ARTIFICIAL VENTILATION; CANCER STAGING; DISEASE CLASSIFICATION; DRUG MECHANISM; HEALTH CARE QUALITY; IMMUNE RESPONSE; INTENSIVE CARE UNIT; MULTIPLE ORGAN FAILURE; SEPTIC SHOCK; SURVIVAL RATE;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; APACHE; BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS, PHASE III; CRITICAL CARE; HUMANS; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 31744431565     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3907     Document Type: Note

References (18)

1. Bone R, Balk R, Cerra F, Dellinger RP, Fein A, Knaus W, Sibbald W: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101: 1644-1655.
2. Marshall JC, Vincent J-L, Fink MP, Cook DJ, Rubenfeld G, Foster D, Faist E, Reinhart K: Measures, markers, and mediators: Towards a staging system for clinical sepsis. Crit Care Med 2003, 31:1560-1567.
3. Levy MM, Fink M, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J-L, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 34:1250-1256.
4. Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A: Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care 2005, 9:R607-R622.
5. Eichacker PQ, Oarent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of anti-inflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Resp Crit Care Med 2002, 166:1197-1205.
6. Bernard GR, Vincent J-L, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
7. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341.
8. Marshall JC, Panacek EA, Teoh L, Barchulk W: Modelling organ dysfunction as a risk factor, outcome, and measure of biologic effect in sepsis: Results of the MONARCS trial. Crit Care Med 2001, 28:A46.
9. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E, the Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group: A multicentre randomized controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999, 340:409-417.
10. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996, 334:1697-1702.
11. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004, 32:21-30.
12. Marshall JC: Such stuff as dreams are made on: Mediator-targeted therapy in sepsis. Nature Rev Drug Disc 2003, 2:391-405.
13. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317:654-658.
14. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987, 317:659-665.
15. Annane D, Sebille V, Charpentier C, Bollaert P-E, Francois B, Korach J-M, Capellier G, Cohen Y, Azoulay E, Troche G, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 2002, 288:862-871.
16. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
17. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995, 333:1025-1032.
18. 2 fragment afelimomab in patients with severe sepsis stratified by IL-6 level. Crit Care Med 2004, 32:2173-2182.